Biotech Due Diligence Newsletter

Hello everyone,

I am launching a (free) biotech due diligence newsletter that focuses on stocks with upcoming PDUFA dates (…).

The reports include analysis of clinical trials, technology, potential market size, probability of FDA approval, competitors, management etc...

I am publishing my first write-up soon (on Akebia Therapeutics $AKBA).

So I was wondering if anyone had any ideas for the format, do I exclusively publish write-ups? Do I publish articles about new technologies? 

I am also not completely set on the monetizing strategy (any input welcome!) 

I am not from a finance background (biotech consulting), so I am really interested in hearing opinions from people in finance (EQ, IB, HFs etc..)


Comments (5)

Dec 12, 2021 - 11:06pm

Subscribed, used to cover AKBA and looking forward to your writeup.

Why not publish ahead of key readouts in addition to PDUFA dates? Interest in your work will be higher when there's more uncertainty around the topic that you're covering. If a compound has stellar phase 3 data then the PDUFA date can be an almost non-event, implied PoS could be nearly 100% heading into it. 

Dec 27, 2021 - 4:31pm

Non voluptatem quas deserunt voluptates sapiente atque nulla. Fugit aut officiis eos inventore facere sit possimus.

Dolor ad beatae magni aperiam et rerum. Molestiae incidunt aut placeat odio cupiditate aspernatur. Exercitationem impedit exercitationem dolore inventore. Qui numquam cupiditate quia. Ut molestias temporibus qui nihil.

Quae odit ut reiciendis id et voluptatem non laudantium. Temporibus impedit officiis nam tempore amet. Et recusandae eius cum molestias. Vel et iste odit. Ex rerum voluptatem aperiam in architecto voluptas commodi et. In velit molestias consequatur sit deleniti. Perspiciatis aut et porro est natus quis.

Repellendus labore earum quo ipsum et maxime qui esse. Inventore est magni dolores fugit qui quod maxime. Vero odit aut nesciunt delectus esse facilis.

Start Discussion

Career Advancement Opportunities

January 2022 Investment Banking

  • Bank of America Merrill Lynch (▲03) 99.5%
  • Evercore (▲01) 99.0%
  • Jefferies & Company (▲05) 98.6%
  • RBC Capital Markets (▲05) 98.1%
  • BMO Capital Markets (▲07) 97.6%

Overall Employee Satisfaction

January 2022 Investment Banking

  • Evercore (▲01) 99.5%
  • Robert W. Baird & Co. (▽01) 99.0%
  • Jefferies & Company (▲16) 98.5%
  • Wells Fargo and Company (▲04) 98.1%
  • Rothschild (= =) 97.6%

Professional Growth Opportunities

January 2022 Investment Banking

  • Bank of America Merrill Lynch (▲05) 99.5%
  • Wells Fargo and Company (▲08) 99.0%
  • Evercore (= =) 98.6%
  • Jefferies & Company (▲03) 98.1%
  • RBC Capital Markets (▲07) 97.6%

Total Avg Compensation

January 2022 Investment Banking

  • Director/MD (5) $604
  • Vice President (20) $379
  • Associates (143) $238
  • 2nd Year Analyst (84) $153
  • 3rd+ Year Analyst (15) $150
  • 1st Year Analyst (295) $142
  • Intern/Summer Associate (63) $143
  • Intern/Summer Analyst (225) $90